rhPro-UK

DRUG2 trials

Sponsors

Tasly Biopharmaceuticals Co., Ltd., The First Affiliated Hospital of Zhengzhou University

Conditions

Acute Ischemic Stroke

Phase 3

rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)

CompletedNCT05700591

Tasly Biopharmaceuticals Co., Ltd.Acute Ischemic Stroke

Start: 2023-01-29End: 2024-03-14Updated: 2024-07-26

Pro-urokinase for Extended-Window Posterior Circulation Stroke

Not yet recruitingNCT07617870

The First Affiliated Hospital of Zhengzhou UniversityAcute Ischemic Stroke

Start: 2026-06-01End: 2028-06-30Target: 586Updated: 2026-06-01

Related Papers

Safety and efficacy of intravenous recombinant human prourokinase for acute ischaemic stroke within 4·5 h after stroke onset (PROST-2): a phase 3, open-label, non-inferiority, randomised controlled trial.

2024-11-2919 citations

RhPro-UK in acute ischemic stroke within 4.5 h of stroke onset trial-2 (the PROST-2 study): Rationale and design of a multicenter, prospective, randomized, open-label, blinded-endpoint, controlled phase 3 non-inferiority trial

International Journal of Stroke2024-06-224 citations